|Hospital:||Netherlands Cancer Institute|
|Patients: This Phase II study involved 40 patients with malignant pleural mesothelioma. Thirty-four patients were men, and six were women. The median age was 62 years. All but one patient was exposed to asbestos. Twenty-five patients had stage 3 or 4 disease. Twenty patients had received prior chemotherapy, radiotherapy, or surgery.|
Treatment: The treatment consisted of one biologic agent: thalidomide. Thalidomide is thought to be an anti-angiogenesis agent that helps stop new blood vessels from forming.
Toxicities: Grade 2-3 toxicities included an allergic reaction, neurotoxicity, and constipation.
Results: The median survival was 7.6 months (230 days).
Correspondence: Paul Baas, MD